Clinical Trial Update: Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and antiviral activity of HIV broadly neutralizing antibodies PGT121.414.LS alone and with VRC0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PGT121.414.LS
• VRC07-523LS

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2024-12-13